The committee will hear updates on certain supplemental biologics license applications (sBLAs) approved under 21 CFR 601.40 (subpart E, accelerated approval regulations) with confirmatory trial(s) that have not verified clinical benefit.
Back to All Events
Earlier Event: April 15
Cellular, Tissue, and Gene Therapies Advisory Committee
Later Event: May 6
Arthritis Advisory Committee Meeting